Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akira Yokoi

Showing results (131-140 of 132) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 132 results.
Molecular Cancer Therapeutics|February 25, 2014
Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphomaSarah K Knutson, Satoshi Kawano, Yukinori Minoshima, et al.
Cancer Research|January 7, 2021
E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt SignalingKazuhiko Yamada, Yusaku Hori, Satoshi Inoue, et al.
Pageof 14

Showing results (131-140 of 132) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 132 results.
Molecular Cancer Therapeutics|February 25, 2014
Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphomaSarah K Knutson, Satoshi Kawano, Yukinori Minoshima, et al.
Cancer Research|January 7, 2021
E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt SignalingKazuhiko Yamada, Yusaku Hori, Satoshi Inoue, et al.
Pageof 14